Abstract
MicroRNAs (miRNAs) are an emerging class of highly conserved, non-coding small RNAs that regulate gene expression on the post-transcriptional level by inhibiting the translation of protein from mRNA or by promoting the degradation of mRNA. The involvement of miRNAs in the regulation of lipid metabolism, inflammatory response, cell cycle progression and proliferation, oxidative stress, platelet activation, endothelial function, angiogenesis and plaque formation and rapture indicates important roles in the initiation and progression of atherosclerosis. In the light of this evidence we will review the role of miRNAs in atherosclerosis.
Keywords: microRNAs, atherosclerosis, inflammation, endothelial function.
Current Topics in Medicinal Chemistry
Title:MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Volume: 13 Issue: 13
Author(s): Gerasimos Siasos, Christina Kollia, Vasiliki Tsigkou, Efthimia K. Basdra, Maria Lymperi, Evangelos Oikonomou, Eleni Kokkou, Porfyrios Korompelis and Athanasios G. Papavassiliou
Affiliation:
Keywords: microRNAs, atherosclerosis, inflammation, endothelial function.
Abstract: MicroRNAs (miRNAs) are an emerging class of highly conserved, non-coding small RNAs that regulate gene expression on the post-transcriptional level by inhibiting the translation of protein from mRNA or by promoting the degradation of mRNA. The involvement of miRNAs in the regulation of lipid metabolism, inflammatory response, cell cycle progression and proliferation, oxidative stress, platelet activation, endothelial function, angiogenesis and plaque formation and rapture indicates important roles in the initiation and progression of atherosclerosis. In the light of this evidence we will review the role of miRNAs in atherosclerosis.
Export Options
About this article
Cite this article as:
Siasos Gerasimos, Kollia Christina, Tsigkou Vasiliki, Basdra K. Efthimia, Lymperi Maria, Oikonomou Evangelos, Kokkou Eleni, Korompelis Porfyrios and Papavassiliou G. Athanasios, MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis, Current Topics in Medicinal Chemistry 2013; 13(13) . https://dx.doi.org/10.2174/15680266113139990099
DOI https://dx.doi.org/10.2174/15680266113139990099 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Advantages and Limitations of Transgenic Mice: The Role of the Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger in Cardiac Electrophysiology and Arrhythmia
Current Medicinal Chemistry Alternative Pharmacological Interventions that Limit Myocardial Infarction
Current Medicinal Chemistry Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus
Current Cardiology Reviews Evaluation of the Cardioprotective Effect of Granulocyte Colony Stimulating Factor in Patients with Carbon Monoxide Poisoning
Protein & Peptide Letters Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Patent Selections:
Recent Patents on Nanotechnology Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists
Current Computer-Aided Drug Design A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Cardiac Calmodulin Kinase: A Potential Target for Drug Design
Current Medicinal Chemistry Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Drug Therapy Aimed at Adenylyl Cyclase to Regulate Cyclic Nucleotide Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Myocardial Ischemia/Reperfusion Injury: Potential of TRPV1 Agonists as Cardioprotective Agents
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in Taxane Drug Delivery
Current Drug Delivery Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology